NexgenRx Inc.
NXG.V
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 11.29% | 17.29% | 16.13% | 11.72% | 7.75% |
| Total Other Revenue | 5.15% | 1.69% | 23.27% | 47.08% | 87.96% |
| Total Revenue | 11.04% | 16.66% | 16.39% | 12.80% | 9.64% |
| Cost of Revenue | 5.55% | 6.63% | 20.55% | 15.10% | 11.13% |
| Gross Profit | 12.53% | 19.47% | 15.27% | 12.20% | 9.24% |
| SG&A Expenses | 4.20% | 8.75% | 12.80% | 13.25% | 11.68% |
| Depreciation & Amortization | -5.65% | -4.58% | -5.10% | -4.68% | -7.05% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.60% | 7.05% | 12.71% | 11.85% | 9.58% |
| Operating Income | 873.41% | 924.36% | 2,362.42% | 213.56% | 16.21% |
| Income Before Tax | 2,895.67% | 431.81% | 284.42% | 103.45% | 26.33% |
| Income Tax Expenses | 1,431.25% | 1,417.62% | -84.01% | -83.00% | -83.13% |
| Earnings from Continuing Operations | 1,124.09% | 285.90% | 182.73% | 90.51% | 69.00% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1,124.09% | 285.90% | 182.73% | 90.51% | 69.00% |
| EBIT | 873.41% | 924.36% | 2,362.42% | 213.56% | 16.21% |
| EBITDA | 53.25% | 88.94% | 50.44% | 17.56% | 4.76% |
| EPS Basic | 238.71% | 171.43% | 106.06% | -3.85% | -40.91% |
| Normalized Basic EPS | 3,550.00% | 435.00% | 258.33% | 116.67% | 33.33% |
| EPS Diluted | 194.74% | 161.90% | 89.47% | -9.68% | -40.74% |
| Normalized Diluted EPS | 3,450.00% | 447.37% | 263.64% | 116.67% | 50.00% |
| Average Basic Shares Outstanding | 0.45% | 0.59% | 0.68% | 0.56% | 0.35% |
| Average Diluted Shares Outstanding | 1.92% | -0.39% | -0.31% | -0.38% | -0.54% |
| Dividend Per Share | -1.35% | -1.35% | 100.00% | -1.33% | 94.74% |
| Payout Ratio | 1.06% | 1.33% | 3.01% | -8.93% | -4.12% |